Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid

Colombat, P; Delwel, Ruud; Gurp, R van; Touw, Ivo P.; Löwenberg, Bob

doi:10.1016/0145-2126(91)90009-i

Cited by 28 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many of these studies are in addition relatively small, and the patients are often heterogeneous with regard to prognostic factors and FAB classification. However, the following conclusions are justified based on the representative studies summarized in Table 1: A) AML blasts can be induced to differentiate in several myeloid directions, and the same differentiation response can often be induced by different cytokines [26][27][28][29][30][31][32][33][34]; B) a certain cytokine or cytokine combination usually induces differentiation only for a subset of patients, and the direction of differentiation often varies between patients [27,29]; C) differentiation induction can be independent of the effects on blast proliferation, and D) the direction of differentiation often shows no correlation with FAB classification (i.e., previous signs of differentiation) [27,[29][30][31]. Thus, in contrast to the predictable effects of differentiation induction in APL, the effects in other AML subsets are difficult to predict in individual patients.…”

Section: Differentiation Induction In Aml Cells With Non-apl Phenotypmentioning

confidence: 99%

“…Although the effects of various cytokines on AML cell (native blasts and AML cell lines) proliferation and viability have been extensively studied, relatively few studies have examined effects of single cytokines, cytokine combinations, or cytokines plus vitamin-D 3 on differentiation of native AML blasts [26][27][28][29][30][31][32][33][34]. Many of these studies are in addition relatively small, and the patients are often heterogeneous with regard to prognostic factors and FAB classification.…”

Section: Differentiation Induction In Aml Cells With Non-apl Phenotypmentioning

confidence: 99%

See 1 more Smart Citation

New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities

Bruserud

Gjertsen

2000

STEM CELLS

View full text Add to dashboard Cite

should be regarded as a promising therapeutic approach, especially as a part of immunotherapy or in combination with intensive chemotherapy to increase the susceptibility of AML blasts to drug-induced apoptosis. Although the morphology-based French-American-British classification was used to identify APL as an AML subset that required a special treatment, it seems unlikely that this classification alone can be used to identify new subsets of AML patients with special therapeutic requirements. Future studies on differentiation induction in AML should therefore focus on A) the identification of therapeutic agents with more predictable effects; B) the use of clinical and laboratory parameters to define new subsets of AML patients in which differentiation induction has a predictable and beneficial effect, and C) the characterization of how AML blast sensitivity to drug-induced apoptosis is altered by differentiation induction.

show abstract

Section: Differentiation Induction In Aml Cells With Non-apl Phenotypmentioning

confidence: 99%

Section: Differentiation Induction In Aml Cells With Non-apl Phenotypmentioning

confidence: 99%

New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities

Bruserud

Gjertsen

2000

STEM CELLS

View full text Add to dashboard Cite

show abstract

“…FAB diagnosis ( Bennett et al , 1985 ) included three M2, five M4 and two M5. T lymphocytes were removed after Ficoll‐Isopaque centrifugation by E‐rosetting with sheep red blood cells and AML cells, then cryopreserved in dimethylsulphoxide (DMSO), as previously described ( Santini et al , 1991 ). After thawing and washing AML blasts were depleted of adherent cells following incubation in serum‐free medium ( Salem et al , 1988 ) in plastic culture flasks (250 ml, Greiner, Germany) and then cultured.…”

Section: Methodsmentioning

confidence: 99%

Butyrate‐stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells

et al. 1998

View full text Add to dashboard Cite

The rapid degradation and subsequent lack of efficacy of n-butyric acid in vivo has been improved by the synthesis of monosaccharide stable pro-drugs of butyric acid. We studied the effects of D1 (O-n-butanoyl-2,3-O-isopropylidene-alpha-D-mannofuranoside), G1 (1-O-n-butanoyl-D,L-xylitol), and F1 (1-O-n-butanoyl 2,3-O-isopropylidene-D,L-xylitol) on the maturation and proliferation of AML cell lines HL 60 and FLG 29.1 and of purified blast cells from 10 cases of de novo acute myeloid leukaemia (AML). AML cell maturation was measured by surface antigen expression, morphology and cytochemistry. Toxicology in mice was also evaluated (DL50 1000 mg/kg). In HL 60 cells G1 and D1 increased the expression of CD15 and CD11a (presenting 62% of promyelo-metamyelocytes), and in 7/10 cases of primary AMLs that of CD11a, CD11b, CD15, and myeloperoxidase. D1, G1 and F1 induced a dose-dependent inhibition of tritiated thymidine uptake. Apoptosis (evaluated by flow cytometry and agarose gel electrophoresis) was induced in AML blasts by D1 and F1 (79% and 94% respectively for HL 60 cells) and, with less effect, by G1 (27%). The persistence of maturative and apoptotic activity in these new pro-drugs of butyric acid, hydrolysed only inside the tumour cell, suggests a possible use in differentiation therapy of myelodysplastic syndromes and AMLs.

show abstract

“…In addition, many of these studies are relatively small, and the patients are often heterogeneous with regard to prognostic factors and FAB classification. However, the following conclusions are justified based on the representative studies summarized in Table 1: A) AML blasts can be induced to differentiate in several myeloid directions, and the same differentiation response can often be induced by different cytokines [23][24][25][26][27][28][29][30][31]; B) a certain cytokine or cytokine combination usually induces differentiation only for a subset of patients, and the direction of differentiation often varies between patients [24,26]; C) differentiation induction can be independent of the effects on blast proliferation, and D) the direction of differentiation often shows no correlation with FAB classification (i.e., previous signs of differentiation) [24,[26][27][28]. Thus, in contrast to the predictable effects of differentiation induction in APL, the effects in other AML subsets are difficult to predict in individual patients.…”

Section: Cytokine Effects On Aml Blast Differentiation In Vitromentioning

confidence: 99%

“…Although the effects of various cytokines on AML cell (native blasts and AML cell lines) proliferation and viability have been extensively studied, relatively few studies have examined effects of single cytokines, cytokine combinations or cytokines+vitamin-D 3 on differentiation of native AML blasts [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]. In addition, many of these studies are relatively small, and the patients are often heterogeneous with regard to prognostic factors and FAB classification.…”

Section: Cytokine Effects On Aml Blast Differentiation In Vitromentioning

confidence: 99%

Induction of Differentiation and Apoptosis— A Possible Strategy in the Treatment of Adult Acute Myelogenous Leukemia

2000

View full text Add to dashboard Cite

A differentiation block with accumulation of immature myeloid cells characterizes acute myelogenous leukemia (AML). However, native AML cells often show some morphological signs of differentiation that allow a classification into different subsets, and further differentiation may be induced by exposure to various soluble mediators, e.g., all trans-retinoic acid (ATRA) and several cytokines. Combination therapy with ATRA and chemotherapy should now be regarded as the standard treatment for the acute promyelocytic leukemia variant of AML. Several agents can induce leukemic cell differentiation for other AML subtypes, although these effects differ between patients. Differentiation may then be associated with induction of apoptosis, and differentiation-inducing therapy may therefore become useful in combination with intensive chemotherapy to increase the susceptibility of AML blasts to drug-induced apoptosis. However, it should be emphasized that differentiation and apoptosis can occur as separate events with different regulation in AML cells, and future studies in AML should therefore focus on: A) the identification of new agents with more predictable effects on differentiation and apoptosis; B) the use of clinical and laboratory parameters to define new subsets of AML patients in which differentiation/apoptosis induction has a predictable and beneficial effect, and C) further characterization of how AML blast sensitivity to drug-induced apoptosis is modulated by differentiation induction.

show abstract

Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid

Cited by 28 publications

References 27 publications

New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities

New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities

Butyrate‐stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells

Induction of Differentiation and Apoptosis— A Possible Strategy in the Treatment of Adult Acute Myelogenous Leukemia

Contact Info

Product

Resources

About